What’s the current market cap for Incyte stock?

Incyte (INCY) has a market cap of $19B as of May 22, 2026.

What is the P/E ratio for Incyte stock?

The price to earnings (P/E) ratio for Incyte (INCY) stock is 13.8 as of May 22, 2026.

Does Incyte stock pay dividends?

No, Incyte (INCY) stock does not pay dividends to its shareholders as of May 22, 2026.

When is the next Incyte dividend payment date?

Incyte (INCY) stock does not pay dividends to its shareholders.

What is the beta indicator for Incyte?

Incyte (INCY) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Incyte stock | $INCY Share Price

13:30

15:10

16:45

18:25

20:00

About Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

Ticker

$INCY

Sector

Health

Primary listing

NASDAQ

Employees

2,844

Headquarters

Wilmington, United States

Website

www.incyte.com

Incyte Metrics

BasicAdvanced

$19bn

13.80

$7.06

0.80

What the Analysts think about Incyte

Analyst ratings (Buy, Hold, Sell) for Incyte stock.

Bulls say / Bears say

The frontMIND Phase 3 study for Incyte’s treatment targeting diffuse large B-cell lymphoma achieved its main goal of progression-free survival, paving the way for a planned U.S. label expansion in first-line therapy in the first half of 2026.

Incyte reported total revenue of $1.51 billion in the fourth quarter of 2025 (up 28% year-over-year) and $5.14 billion for the full year 2025 (up 21% year-over-year), surpassing company guidance and highlighting strong commercial performance of Jakafi, Opzelura, Niktimvo, and Monjuvi.

A new dermatology candidate demonstrated lasting symptom relief in two advanced trials, reinforcing the strength and credibility of Incyte’s dermatology pipeline.

Incyte forecast 2026 annual sales of Opzelura below Wall Street expectations, increasing concerns over its ability to compensate for upcoming Jakafi patent expirations.

Incyte's 2026 net product revenue guidance of $4.77–4.94 billion is significantly below the consensus estimate of approximately $5.52 billion, raising doubts about the company's growth prospects as Jakafi nears the end of its patent protection in 2028.

Incyte paused development of Opzelura for prurigo nodularis after the FDA required further clinical data, delaying progress for a potentially major dermatology indication.

Data summarised monthly by Lightyear AI. Last updated on 27 Apr 2026.

Incyte Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Incyte Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $INCY

Capital at risk

Market open

Upcoming events

No upcoming events

Bulls say / Bears say

A new dermatology candidate demonstrated lasting symptom relief in two advanced trials, reinforcing the strength and credibility of Incyte’s dermatology pipeline.

Incyte forecast 2026 annual sales of Opzelura below Wall Street expectations, increasing concerns over its ability to compensate for upcoming Jakafi patent expirations.

Incyte paused development of Opzelura for prurigo nodularis after the FDA required further clinical data, delaying progress for a potentially major dermatology indication.

Data summarised monthly by Lightyear AI. Last updated on 27 Apr 2026.